pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Enhertu
drug · antibody drug conjugate
save

trastuzumab deruxtecan

Marketedupdated 3mo ago
by Daiichi Sankyo Co Ltd🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugENHERTU78 co-mentions · 13 sources
  • tagApproval78 co-mentions · 13 sources
  • drugtrastuzumab39 co-mentions · 13 sources

Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.

indications

investigational
NSCLCColorectal Cancer

targets

Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1

all catalysts(13)

approval · 13
Dec 20, 2019
approval
7y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 15, 2021
approval
6y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
4y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
4y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 5, 2022
approval
4y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 11, 2022
approval
4y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Nov 4, 2022
approval
4y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Feb 15, 2024
approval
3y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Apr 5, 2024
approval
2y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
2y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
2y ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
8mo ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
8mo ago
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
view all 13 catalysts →

Trials studying trastuzumab deruxtecan

  • —A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)active not recruitingn=257
  • phase1FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3recruitingn=677
  • —DESTINY Breast Respond HER2-(Ultra)Low Europerecruitingn=2,295
  • phase3Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancerrecruitingn=620
  • phase2A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCactive not recruitingn=72
  • phase2A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinomarecruitingn=100
  • phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignanciesrecruitingn=695
  • phase3DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancerrecruitingn=600
more trials →

News(10)

  • AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
    AstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…
    endpoints · 3d ago
  • ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
    If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
    biospace · 17d ago
  • Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
    With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
    biospace · 21d ago
  • AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
    AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
    fiercebiotech · 25d ago
  • ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
    For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
    fiercebiotech · 1mo ago
  • Merck ADC, in China study, shows potential to replace chemo in lung cancer
    The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
    biopharma_dive · 1mo ago
  • STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
    A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching ​an agreement allowing Teva to market a generic ‌version of Forteo
    stat · 1mo ago
  • STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents
    A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.
    stat · 1mo ago
  • STAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and more
    U.S. health secretary Robert F. Kennedy Jr. is pressing forward with his effort to help Americans stop taking SSRI antidepressants
    stat · 1mo ago
  • STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
    German lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the government
    stat · 1mo ago
view all news mentions →
brand
Enhertu
trade names
Enhertu
generic
fam-trastuzumab deruxtecan-nxki
MOA
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
indication
Metastatic Colorectal Cancer
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 46m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?